Product Name: IDH1 (129-135)
Product Number: PE-01BFS99
Size: 200 µg      Price:29.00
1 mg      $US59.00
5 mg      129.00
Peptide Name: IDH1 (129-135)

Product Use: The R132H mutation, which inhibits IDH1 enzyme activity with pyruvate, is a commonly found in glioblastomas and some other forms of human cancers.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: IIGHHAY

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 983.1 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder
Peptide Form: Solid

Storage Conditions: -20°C

Scientific Background: IDH1 is an oxidoreductase that catalyzes the third step in the TCA cycle in mitochondria: Isocitrate + NADP+ = alpha-ketoglutarate (alpha-KG) + CO2 + NADPH. Alpha-KG is an activator of dioxygenases that hydroxylate the transcription factor HIF and induce its degradation by VHL. As HIF turns on oncogenic pathways, IDH1 has apparent tumor suppressor activity. Somatic mutations affecting R132 are found in 80% of grade II?III gliomas and secondary glioblastomas in humans, and cause disease in a tissue-specific fashion. Only a single copy of the gene has been found to be mutated in tumours. Mutations of R132 to H, C, S, G, V, or L have been reported to be neomorphic, blocking the conversion of isocitrate to alpha-KG. Instead, alpha-KG is converted to R(-)-2-hydroxyglutarate (2HG). Elevated levels of 2HG correlate with an elevated risk of malignant brain tumours. Neomorphic mutations in IDH1 and IDH2 convert alpha-KG to 2-hydroxyglutarate (2-HG) occur in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML).